Navigation Links
Heartburn Meds Won't Help, May Harm Kids With Asthma
Date:1/24/2012

By Serena Gordon
HealthDay Reporter

TUESDAY, Jan. 24 (HealthDay News) -- Children with asthma who don't have heartburn and other signs of gastroesophageal reflux don't get additional asthma control from acid-reducing medications, according to new research.

And, taking these medications when there are no digestive issues increases a child's risk of developing a respiratory infection, reports the study.

"There's a strong epidemiological link between acid reflux and asthma," explained study co-author Janet Holbrook, an associate professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore. As a result, current asthma guidelines call for evaluating people with asthma for acid reflux, Holbrook said.

Because definitive tests for excess acid production can cause children discomfort, some doctors may choose to do a trial of acid-suppressing medications called proton pump inhibitors (PPIs). Some common brand names in this class of medication are Prilosec, Prevacid and Nexium.

"Our findings suggest that physicians should not take kids with poorly controlled asthma and test whether PPIs will help," said Holbrook.

Results of the study are published in the Jan. 25 issue of the Journal of the American Medical Association. The study was funded by the U.S. National Institutes of Health and conducted by the American Lung Association Asthma Clinical Research Centers.

Asthma and gastroesophageal reflux (GER or GERD) are common conditions in children. Youngsters with asthma often have symptoms of gastroesophageal reflux. In adults, PPIs seem to help people with asthma who also have symptoms of gastroesophageal reflux, but not those who don't have symptoms, such as frequent heartburn.

The current study included 306 children recruited from 19 centers across the United States between 2007 and 2010. The average age was 11 years. All had poor asthma control despite receiving treatment with inhaled corticosteroids.

The children were randomly assigned to receive either lansoprazole -- a PPI -- or a placebo daily for six months. The dose of lansoprazole was based on the child's weight.

Asthma improvement was assessed through a change in the Asthma Control Questionnaire, which has a scale of 0 to 6. A change of 0.5 is considered clinically significant. Lung function was also measured.

After six months, there were no statistically significant differences between the groups. The average change in the Asthma Control Questionnaire score was only 0.2, and there were no statistically significant changes in lung function, quality of life or rate of asthma flare-ups.

In addition, among 115 children who also had a 24-hour esophageal acid study, 43 percent were found to have elevated levels of acid production. Yet even in this group, treatment with lansoprazole didn't improve asthma symptoms over placebo.

Holbrook said although this study only looked at one PPI, she believes the results would hold true for other medications in this class of drugs.

Children taking lansoprazole had about a 30 percent higher risk of respiratory infections and sore throats in this study. PPIs were also associated with a difference in the risk of activity-related bone fractures, although the difference was not statistically significant, according to an accompanying editorial in the same issue of the journal.

"PPIs do not improve asthma in children who do not have symptoms of GER/GERD, and it is unlikely to be of great benefit even in children who do have such symptoms," said the editorial author, Dr. Fernando Martinez, director of the Arizona Respiratory Center at the University of Arizona in Tucson.

"The substantial increase in use of PPIs in children during the last decade is worrisome and unwarranted," he wrote.

Still, Martinez advised parents not to abruptly discontinue any medications. Parents "should consult their pediatricians, who can best evaluate the clinical situation for each child," he said.

Holbrook agreed and said if a child is on a PPI, it's reasonable for parents to ask why. She noted that these medications may come with an additional risk and cost, and they may not have any additional benefit.

"If your child is on a PPI for asthma, it's not an effective treatment. These medications are approved for the treatment of acid reflux," said Holbrook.

More information

Learn more about asthma treatment from the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Janet Holbrook, M.P.H., Ph.D., associate professor, epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore; Fernando Martinez, M.D., director, Arizona Respiratory Center and Swift-McNear Professor of Pediatrics, University of Arizona, Tucson; Jan. 25, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Chronic Heartburn a Growing Problem in U.S.
2. Heartburn treatment may extend survival in IPF patients
3. Popular Heartburn Meds May Boost Fracture Risk
4. Scott & White Healthcare -- Round Rock performing surgery without incisions for heartburn
5. Heartburn Drugs May Raise Pneumonia Risk
6. For Most, Chronic Heartburn Not a Big Risk for Esophageal Cancer
7. No Link Between Heartburn Drugs and Birth Defects: Study
8. Heartburn Drugs, Plavix Seem Safe to Take Together
9. Plavix, Heartburn Drug Safe to Take Together: Study
10. FDA Warns of Fracture Risk With Popular Heartburn Drugs
11. Coming Soon: A Low-Heartburn Coffee?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Heartburn Meds Won't Help, May Harm Kids With Asthma
(Date:4/26/2017)... ... April 26, 2017 , ... Intalere, the healthcare industry leader ... “Make Plans for MACRA,” highlighting the impact of the Medicare Access and ... physicians and other clinicians are reimbursed for the care they deliver in Medicare. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... thrilled to announce the ATA 2017 President’s Awards recipients, comprised of organizations ... superior healthcare delivery. , The ATA 2017 President’s Awards recognize individuals ...
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of a pioneering ... , the largest Electronic Medical Records (EMR) provider in South Africa. By using ... a patient’s remote health progress, empowering the patient to take direct responsibility for their ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business ... National Registry of Emergency Medical Technicians and welcomes this organization to ... Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Miami native ... as a dentist. , “I could have never imagined back in 1991 that this ... said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
Breaking Medicine Technology: